New insights into insulin resistance in the diabetic heart

Trends in Endocrinology and Metabolism

Volumn 22, Issue 10, 2011, Pages 394-403

  Gray, Susan ^a   Kim, Jason K ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE;

CELL DEATH; CELL FUNCTION; CELL MEMBRANE; CELL SURVIVAL; CYTOPLASM; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; HEART; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; INSULIN RESISTANCE; KERATINOCYTE; LIPID OXIDATION; LIPOTOXICITY; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCOSE; HEART DISEASES; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA, HEART; MYOCARDIUM; OBESITY; TOR SERINE-THREONINE KINASES;

EID: 80053128750     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.05.001     Document Type: Review

References (109)

1. Wild S., et al. Diab. Care 2004, 27:1047-1053.
2. Grundy S.M., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
3. Eguchi K., et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am. J. Cardiol. 2008, 101:1787-1791.
4. Bell D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diab. Care 2003, 26:2433-2441.
5. Boyer J.K., et al. Prevalence of ventricular diastolic dysfunction in asymptomatic normotensive patients with diabetes mellitus. Am. J. Cardiol. 2004, 93:870-875.
6. Taegtmeyer H., Passmore J.M. Defective energy metabolism of the heart in diabetes. Lancet 1985, 1:139-141.
7. Iozzo P., et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002, 51:3020-3024.
8. Barouch L.A., et al. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ. Res. 2006, 98:119-124.
9. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr. Prob. Cardiol. 1994, 19:59-113.
10. Schaffer J.E. Fatty acid transport: the roads taken. Am. J. Physiol. Endocrinol. Metab. 2001, 282:E239-E246.
11. Coburn C.T., et al. Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues. J. Mol. Neurosci. 2001, 16:117-121.
12. Glatz J.F.C., et al. Cellular fatty acid-binding proteins: their function and physiological significance. Prog. Lipid Res. 1996, 35:243-282.
13. Coburn C.T., et al. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 275:32523-32529.
14. Stanley W.C., et al. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 1997, 34:25-33.
15. Fischer Y., et al. Insulin-induced recruitment of glucose transporters GLUT4 and GLUT1 in isolated rat cardiac myocytes, Evidence for the existence of different intracellular GLUT4 vesicle populations. J. Biol. Chem. 1997, 272:7085-7092.
16. James D.E., et al. Insulin-regulatable tissues express a unique insulin-sensitivei glucose transport protein. Nature 1988, 333:183-185.
17. White M.F., Kahn C.R. The insulin signaling system. J. Biol. Chem. 1994, 269:1-4.
18. Fischer Y., et al. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology 1995, 136:412-420.
19. Abel E.D., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 1999, 104:1703-1714.
20. Tian R., Abel E.D. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001, 103:2961-2966.
21. Belke D.B., et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 2002, 109:629-639.
22. Young L.H., et al. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc. Med. 2005, 15:110-118.
23. Koh H.-J., et al. LKB1 and AMPK and the regulation of skeletal muscle metabolism. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:227-232.
24. Russell R.R., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 2004, 114:495-503.
25. Minokoshi Y., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
26. Kudo N., et al. Characterization of 5(AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim. Biophys. Acta 1996, 1301:67-75.
27. Abu-Elheiga L., et al. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001, 291:2613-2616.
28. Witters L.A., Kemp B.E. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5'-AMP-activated protein kinase. J. Biol. Chem. 1992, 267:2864-2867.
29. Russell R.R., et al. Translocation of myocardial GLUT4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 1999, 277:H643-H649.
30. Marsin A.S., et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischemia. Curr. Biol. 2000, 10:1247-1255.
31. Nishino Y., et al. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc. Res. 2004, 61:610-619.
32. Xing Y., et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem. 2003, 278:28372-28377.
33. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 2007, 100:328-341.
34. Zoncu R., et al. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
35. Um S.H., et al. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006, 3:393-402.
36. Um S.H., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
37. Kumar A., et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010, 59:1397-1406.
38. Kemi O.J., et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J. Cell. Physiol. 2008, 214:316-321.
39. McMullen J.R., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
40. Song X., et al. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am. J. Physiol. Cell Physiol. 2010, 299:C1256-C1266.
41. Zhang D., et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 2010, 120:2805-2816.
42. Kolter T., et al. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am. J. Physiol. 1997, 273:E59-E67.
43. Ohtake T., et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J. Nucl. Med. 1995, 36:456-463.
44. Park S.-Y., et al. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005, 54:3530-3540.
45. Buchanan U., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
46. Zhou Y.T., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1784-1789.
47. Lopaschuk G.D. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrates/lipid metabolism. Coron. Artery Dis. 1996, 7:116-123.
48. Rosen E.D., Spiegelman B.M. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001, 276:37731-37734.
49. Finck B.N., et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 2002, 109:121-130.
50. Park S.-Y., et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-α causes insulin resistance in heart and liver. Diabetes 2005, 54:2514-2524.
51. Kahn C.R. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994, 43:1066-1084.
52. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 2002, 32:14-23.
53. DeFronzo R.A. The triumvirate: beta-cell, muscle, liver, A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
54. Czech M.P., Corvera S. Signaling mechanisms that regulate glucose transport. J. Biol. Chem. 1999, 274:1865-1868.
55. Boudina S., et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 2002, 109:629-639.
56. Randle P.J., et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 281:785-789.
57. Unger R.H. Lipotoxic diseases. Annu. Rev. Med. 2002, 53:319-336.
58. Goldberg I.J. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 1996, 37:693-707.
59. Kim J.K., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7522-7527.
60. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 2007, 19:142-149.
61. Kim J.K., et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 2004, 114:823-827.
62. Kim J.K., et al. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 2001, 108:437-446.
63. Park T.-S., et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid. Res. 2008, 49:2101-2112.
64. 307 via distinct pathways. J. Clin. Invest. 2001, 107:181-189.
65. Lee J., et al. Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H310-H319.
66. Wright J.J., et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc. Res. 2009, 82:351-360.
67. Szczepaniak L.S., et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 2003, 49:417-423.
68. Christoffersen C., et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 2003, 144:3483-3490.
69. Petersen K.F., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
70. Boudina S., et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005, 112:2686-2695.
71. Boudina S., et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119:1271-1283.
72. Laskowski K.R., Russell R.R. Uncoupling proteins in heart failure. Curr. Heart Failure Rep. 2008, 5:75-79.
73. Scheuermann-Freestone M., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040-3046.
74. Gimeno R.E., et al. Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 1997, 46:900-906.
75. Bugger H., Abel E.D. Mitochondria in the diabetic heart. Cardiovasc. Res. 2010, 88:229-240.
76. Boudina S., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56:2457-2466.
77. Duncan J.G., et al. Insulin-resistant hearts exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007, 115:909-917.
78. Axelsen L.N., et al. Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298:R1560-R1570.
79. Hoeks J., et al. Prolonged fasting identifies skeletal muscle mitochondrial dysfunction as consequence rather than cause of human insulin resistance. Diabetes 2010, 59:2117-2125.
80. Wellen K.F., Hotamisligil G.S. Inflammation, stress, diabetes. J. Clin. Invest. 2005, 115:1111-1119.
81. Kanda H., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116:1494-1505.
82. Cinti S., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
83. Xu H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
84. Weisberg S.P., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116:115-124.
85. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
86. Gwechenberger M., et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999, 99:546-551.
87. Kim H.J., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53:1060-1067.
88. Ueki K., et al. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 2004, 24:5434-5446.
89. Shi H., et al. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J. Biol. Chem. 2004, 279:34733-34740.
90. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr. Diab. Rep. 2006, 6:177-181.
91. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
92. Kewalramani G., et al. Muscle insulin resistance: assault by lipids, cytokines, and local macrophages. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:382-390.
93. Hong E.-G., et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 2009, 58:2525-2535.
94. Ribas V., et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERα-deficient mice. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E304-E319.
95. Nunemaker C.S., et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1065-1075.
96. Ko H.J., et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in heart. Diabetes 2009, 58:2536-2546.
97. Sabio G., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
98. Kaufman R.J., et al. The unfolded protein response in nutrient sensing and differentiation. Nat. Rev. Mol. Cell Biol. 2002, 3:411-421.
99. Lee A.H., et al. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol. Cell. Biol. 2003, 23:7448-7459.
100. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
101. Ozcan U., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
102. Lee A.S. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem. Sci. 2001, 26:504-510.
103. Ye R., et al. Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance. Diabetes 2010, 59:6-16.
104. Costanzo-Garvey D.L., et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 2009, 10:366-378.
105. Sabio G., et al. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulin resistance. Mol. Cell. Biol. 2010, 30:106-115.
106. Sabio G., et al. Prevention of steatosis by hepatic JNK1. Cell Metab. 2009, 10:491-498.
107. Sabio G., et al. Role of the hypothalamic-pituitary-thyroid axis in metabolic regulation by JNK1. Genes Dev. 2010, 24:256-264.
108. Djaberi R., et al. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia 2008, 51:1581-1593.
109. Elkeles R.A. Coronary artery calcium and cardiovascular risk in diabetes. Atherosclerosis 2010, 210:331-336.